News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Lannett Company, Inc. Adds Paul Taveira to Board of Directors
May 11, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PHILADELPHIA--(BUSINESS WIRE)--Lannett Company, Inc. (NYSE Amex: LCI), a manufacturer of generic pharmaceuticals, today announced the appointment of Paul Taveira to its board of directors, expanding the company’s board to eight members.
Twitter
LinkedIn
Facebook
Email
Print
People
MORE ON THIS TOPIC
Layoff Tracker
Inovio Slims Down as Lead Asset Nears Market
March 16, 2026
·
36 min read
·
BioSpace Editorial Staff
Earnings
Biotechs Report Regulatory Headaches, High-Stakes Catalysts During Q4 Earnings
March 13, 2026
·
5 min read
·
Annalee Armstrong
Rare diseases
Rare Disease Sales To Soar to $400B+ By 2032 as Small Molecules Resurgent: Evaluate
March 13, 2026
·
2 min read
·
Tristan Manalac
Earnings
Novo Holdings’ Assets Fell 34% in 2025 As Its Namesake Drugmaker Struggled
March 12, 2026
·
1 min read
·
Annalee Armstrong
